drugset / Trial / NCT05955183

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

NCT05955183

Phase 1 Completed 38 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindOther

Summary

This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD5055 after single and multiple doses, orally administered in healthy Japanese and Chinese participants.

Timeline

Start
2023-07-27
Primary completion
2023-12-04
Completion
2023-12-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD5055 Unknown Oral

Indications

No indication recorded.